🚀 VC round data is live in beta, check it out!
ABL Bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for ABL Bio and similar public comparables like Shanghai Junshi, Kolon TissueGene, Cogent Biosciences, PTC Therapeutics and more.
ABL Bio Overview
About ABL Bio
ABL Bio Inc is a Korean biotech research company. The company is engaged in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline products include ABL001 an Bispecific Antibody, ABL201-205 an Antibody Drug Conjugate, T cell engager, Dual Immune Cell Targeting BsAb an Immuno-Oncology, ABL301 an BBB-Penetrating Bispecific Antibody.
Founded
2016
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$6B
ABL Bio Financials
ABL Bio reported last 12-month revenue of $62M and negative EBITDA of ($119M).
In the same LTM period, ABL Bio generated $62M in gross profit, ($119M) in EBITDA losses, and had net loss of ($121M).
Revenue (LTM)
ABL Bio P&L
In the most recent fiscal year, ABL Bio reported revenue of $60M and EBITDA of ($23M).
ABL Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $62M | XXX | $60M | XXX | XXX | XXX |
| Gross Profit | $62M | XXX | $54M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 89% | XXX | XXX | XXX |
| EBITDA | ($119M) | XXX | ($23M) | XXX | XXX | XXX |
| EBITDA Margin | (193%) | XXX | (38%) | XXX | XXX | XXX |
| EBIT Margin | (196%) | XXX | (45%) | XXX | XXX | XXX |
| Net Profit | ($121M) | XXX | ($26M) | XXX | XXX | XXX |
| Net Margin | (196%) | XXX | (43%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
ABL Bio Stock Performance
ABL Bio has current market cap of $6B, and enterprise value of $6B.
Market Cap Evolution
ABL Bio's stock price is $109.28.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6B | $6B | -1.7% | XXX | XXX | XXX | $-0.46 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialABL Bio Valuation Multiples
ABL Bio trades at 97.0x EV/Revenue multiple, and (50.3x) EV/EBITDA.
EV / Revenue (LTM)
ABL Bio Financial Valuation Multiples
As of April 18, 2026, ABL Bio has market cap of $6B and EV of $6B.
Equity research analysts estimate ABL Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ABL Bio has a P/E ratio of (49.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV/Revenue | 97.0x | XXX | 99.6x | XXX | XXX | XXX |
| EV/EBITDA | (50.3x) | XXX | (264.5x) | XXX | XXX | XXX |
| EV/EBIT | (49.5x) | XXX | (219.6x) | XXX | XXX | XXX |
| EV/Gross Profit | 97.0x | XXX | 111.4x | XXX | XXX | XXX |
| P/E | (49.9x) | XXX | (235.5x) | XXX | XXX | XXX |
| EV/FCF | 4.3x | XXX | 3.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified ABL Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
ABL Bio Margins & Growth Rates
ABL Bio's revenue in the last 12 month grew by 15%.
ABL Bio's rule of 40 is (229%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ABL Bio's rule of X is (196%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
ABL Bio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | (193%) | XXX | (38%) | XXX | XXX | XXX |
| EBITDA Growth | (2%) | XXX | 625% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (229%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (196%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 10% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 6% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 105% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 135% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
ABL Bio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| ABL Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Shanghai Junshi | XXX | XXX | XXX | XXX | XXX | XXX |
| Kolon TissueGene | XXX | XXX | XXX | XXX | XXX | XXX |
| Cogent Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| PTC Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Rhythm Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ABL Bio M&A Activity
ABL Bio acquired XXX companies to date.
Last acquisition by ABL Bio was on XXXXXXXX, XXXXX. ABL Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by ABL Bio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialABL Bio Investment Activity
ABL Bio invested in XXX companies to date.
ABL Bio made its latest investment on XXXXXXXX, XXXXX. ABL Bio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by ABL Bio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout ABL Bio
| When was ABL Bio founded? | ABL Bio was founded in 2016. |
| Where is ABL Bio headquartered? | ABL Bio is headquartered in South Korea. |
| Who is the CEO of ABL Bio? | ABL Bio's CEO is Sang-hoon Lee. |
| Is ABL Bio publicly listed? | Yes, ABL Bio is a public company listed on Korea Exchange. |
| What is the stock symbol of ABL Bio? | ABL Bio trades under 298380 ticker. |
| When did ABL Bio go public? | ABL Bio went public in 2018. |
| Who are competitors of ABL Bio? | ABL Bio main competitors are Shanghai Junshi, Kolon TissueGene, Cogent Biosciences, PTC Therapeutics. |
| What is the current market cap of ABL Bio? | ABL Bio's current market cap is $6B. |
| What is the current revenue of ABL Bio? | ABL Bio's last 12 months revenue is $62M. |
| What is the current revenue growth of ABL Bio? | ABL Bio revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of ABL Bio? | Current revenue multiple of ABL Bio is 97.0x. |
| Is ABL Bio profitable? | No, ABL Bio is not profitable. |
| What is the current EBITDA of ABL Bio? | ABL Bio has negative EBITDA and is not profitable. |
| What is ABL Bio's EBITDA margin? | ABL Bio's last 12 months EBITDA margin is (193%). |
| What is the current EV/EBITDA multiple of ABL Bio? | Current EBITDA multiple of ABL Bio is (50.3x). |
| What is the current FCF of ABL Bio? | ABL Bio's last 12 months FCF is $1B. |
| What is ABL Bio's FCF margin? | ABL Bio's last 12 months FCF margin is 2245%. |
| What is the current EV/FCF multiple of ABL Bio? | Current FCF multiple of ABL Bio is 4.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.